Epitope-driven common subunit vaccine design against <i>H. pylori</i> strains

Pasala, Chiranjeevi; Katari, Sudheer Kumar; Nalamolu, Ravina Madhulitha; Bitla, Aparna R.; Umamaheswari, Amineni

doi:10.1080/07391102.2018.1526714

Cited by 15 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 Four enzymes and three membrane proteins with high predictive antigenicity and molecular weights <110 kDa were proposed as new therapeutic and vaccine targets. 29 In a follow-up in silico study, 30 the authors demonstrated how computational studies on the T-cell epitopes of vaccine candidates may be used to design novel vaccine "cocktails" against multiple H pylori strains. These candidates will need to be tested by proof-of-concept vaccine studies in experimental infection models.…”

Section: Selection Of Novel Protective Antigens and Epitopesmentioning

confidence: 99%

Review: Helicobacter: Inflammation, immunology, and vaccines

Lehours

Ferrero

2019

Helicobacter

View full text Add to dashboard Cite

Chronic inflammation induced by Helicobacter pylori infection is a critical factor in the development of peptic ulcer disease and gastric cancer. Central to this inflammation is the initiation of pro‐inflammatory signaling cascades within epithelial cells, in particular those mediated by two sensors of bacterial cell wall components, nucleotide‐binding oligomerization domain‐containing protein 1 (NOD1) and alpha‐protein kinase 1 (ALPK1). H pylori is, however, also highly adept at mitigating inflammation in the host, thereby restricting tissue damage and favoring bacterial persistence. H pylori modulates host immune responses by altering cytokine signaling in epithelial and myeloid cells, which results in increased proliferation of regulatory T cells and downregulation of effector T‐cell responses. H pylori vacuolating cytotoxin A (VacA) has been shown to play an important role in the dampening of immune responses and induction of immune tolerance capable of protecting against asthma. It is also possible to generate protective immune responses by immunization with various H pylori antigens or their epitopes, in combination with an adjuvant, though this for now has only been shown in mouse models. Novel non‐toxic adjuvants, consisting of modified bacterial enterotoxins or nanoparticles, have recently been developed that may not only enhance vaccine efficacy, but also help translate candidate vaccines to the clinic. This review will summarize the main discoveries in the past year regarding host immune responses to H pylori infection, as well as the design of new vaccine approaches against this infection.

show abstract

Section: Selection Of Novel Protective Antigens and Epitopesmentioning

confidence: 99%

Review: Helicobacter: Inflammation, immunology, and vaccines

Lehours

Ferrero

2019

Helicobacter

View full text Add to dashboard Cite

show abstract

“…This epitope-based vaccine development approach has been explored and proved to be promising in a number of diseases caused by viruses like Herpes simplex virus (Hasan et al, 2019;Kumar et al, 2019), Yellow Fever Virus (Tosta et al, 2019), SARS Coronavirus (Srivastava et al, 2019), Chikungunya (Bappy et al, 2020), Dengue (Sabetian, Nezafat, Dorosti, Zarei, & Ghasemi, 2019), Alkhurma hemorrhagic fever virus (Ul-Rahman & Shabbir, 2019), etc. as well as by other pathogens including Leishmania donovani (Khatoon et al, 2019), Elizabethkingia anophelis (Nain et al, 2019), Flavobacterium columnare (Bhattacharya et al, 2020), Bacillus anthracis (Gupta, Khatoon, Mishra, Verma, & Prajapati, 2019), Streptococcus pneumoniae (Dorosti et al, 2019), Helicobacter pylori (Pasala et al, 2019), etc. Thus, this multi-epitope vaccine construct designed with a multi-dimensional approach helps in the activation of TLR3 along with the innate and specific adaptive immune response that will also be adsorbed from the intestinal lining and will generate a prominent immune response against the deadly Nipah virus.…”

Section: Introductionmentioning

confidence: 99%

Designing of a multi-epitope vaccine candidate against Nipah virus by in silico approach: a putative prophylactic solution for the deadly virus

Majee

Jain

Kumar

2020

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

Nipah virus (NPV) is one of the most notorious viruses with a very high fatality rate. Because of the recurrent advent of this virus and its severe neurological implications, often leading to high mortality, the WHO R&D Blueprint, 2018 has listed the Nipah virus as one of the emerging infectious diseases requiring urgent research and development effort. Yet there is a major layback in the development of effective vaccines or drugs against NPV. In this study, we have designed a stable multivalent vaccine combining several T-cell and B-cell epitopes of the essential Nipah viral proteins with the help of different ligands and adjuvants which can effectively induce both humoral and cellular immune responses in human. Different advanced immune-informatic tools confirm the stability, high immunogenicity and least allergenicity of the vaccine candidate. The standard molecular dynamic cascade analysis validates the stable interaction of the vaccine construct with the human Toll-like receptor 3 (TLR3) complex. Later, codon optimization and in silico cloning in a known pET28a vector system shows the possibility for the expression of this vaccine in a simple organism like E.coli. It is believed that with further in vitro and in vivo validation, this vaccine construct can pose to be a better prophylactic solution to the Nipah viral disease.

show abstract

“…Surface‐exposed membrane proteins were predicted from 826 proteins of 53 H pylori strains by Pasala et al, who proposed novel vaccine cocktails and insights for T‐cell driven subunit vaccine design. Validation of these proposed vaccines is needed to verify their safety and immunogenicity 36 …”

Section: Vaccinesmentioning

confidence: 99%

Review ‐ Helicobacter, inflammation, immunology and vaccines

Robinson

Lehours

2020

Helicobacter

View full text Add to dashboard Cite

Understanding the mechanisms involved in induction and regulation of the immune and inflammatory response to Helicobacter pylori is extremely important in determining disease outcomes. H pylori expresses a plethora of factors that influence the host response. Vaccines against H pylori are desperately needed for the prevention of gastric carcinogenesis, especially with the increasing trends in antimicrobial resistance. This review summarizes some important findings, published between 1 April 2019 and 31 March 2020, in the areas of H pylori‐mediated inflammation, immunity and vaccines.

show abstract

Epitope-driven common subunit vaccine design against H. pylori strains

Cited by 15 publications

References 31 publications

Review: Helicobacter: Inflammation, immunology, and vaccines

Review: Helicobacter: Inflammation, immunology, and vaccines

Designing of a multi-epitope vaccine candidate against Nipah virus by in silico approach: a putative prophylactic solution for the deadly virus

Review ‐ Helicobacter, inflammation, immunology and vaccines

Contact Info

Product

Resources

About